| scholarly article | Q13442814 |
| P2093 | author name string | Daisuke Takei | |
| Hiroyuki Okada | |||
| Kazuhide Yamamoto | |||
| Keisuke Hori | |||
| Jun Kato | |||
| Asuka Nakarai | |||
| Keita Harada | |||
| Sakiko Hiraoka | |||
| Sakuma Takahashi | |||
| Toshihiro Inokuchi | |||
| Yuki Moritou | |||
| Mitsuhiro Akita | |||
| P2860 | cites work | CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells | Q24310570 |
| Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. | Q33183129 | ||
| Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease | Q34255362 | ||
| The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review | Q34559065 | ||
| Inflammatory bowel disease Part 1: ulcerative colitis--pathophysiology and conventional and alternative treatment options. | Q35208388 | ||
| Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients | Q35596004 | ||
| Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. | Q35597079 | ||
| Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury | Q35849153 | ||
| Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study | Q36328183 | ||
| Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression | Q36671830 | ||
| Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis | Q36879683 | ||
| Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission | Q37111911 | ||
| CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease | Q37314595 | ||
| Clinical implications of mucosal healing for the management of IBD. | Q37641754 | ||
| Mucosal healing in inflammatory bowel diseases: a systematic review | Q38030351 | ||
| Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort | Q40186159 | ||
| Platelet derived CD154 (CD40 ligand) and febrile responses to transfusion | Q43662394 | ||
| Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease | Q45181649 | ||
| Evaluation of mucosal healing of ulcerative colitis by a quantitative fecal immunochemical test | Q45389254 | ||
| Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. | Q51739537 | ||
| Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial | Q59120396 | ||
| Mucosal Healing Predicts Late Outcomes After the First Course of Corticosteroids for Newly Diagnosed Ulcerative Colitis | Q61657076 | ||
| Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study | Q68206432 | ||
| The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease | Q72279791 | ||
| Platelets: unindicted coconspirators in inflammatory tissue injury | Q73281439 | ||
| Mean platelet volume: a useful marker of inflammatory bowel disease activity | Q73697850 | ||
| Reticulated platelet levels in patients with ulcerative colitis | Q80430161 | ||
| Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis | Q84490301 | ||
| Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study | Q84735757 | ||
| P433 | issue | 48 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ulcerative colitis | Q1477 |
| P304 | page(s) | 18367-18374 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Prognosis of ulcerative colitis differs between patients with complete and partial mucosal healing, which can be predicted from the platelet count | |
| P478 | volume | 20 |
| Q89264047 | An Elevated Platelet Count Increases the Risk of Relapse in Ulcerative Colitis Patients with Mucosal Healing |
| Q93355469 | Blood biomarkers reflect integration of severity and extent of endoscopic inflammation in ulcerative colitis |
| Q50510379 | Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. |
| Q89483676 | Does Medical Acceleration Improve Outcomes in Ulcerative Colitis Patients Who Are in Clinical Remission but Have Endoscopic Inflammation? |
| Q53171219 | Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission. |
| Q53564533 | Evaluation of Mucosal Healing in Ulcerative Colitis by Fecal Calprotectin Vs. Fecal Immunochemical Test. |
| Q87844509 | Fecal Calprotectin in Assessing Endoscopic and Histological Remission in Patients with Ulcerative Colitis |
| Q50221428 | Fecal Immunochemical Test and Fecal Calprotectin Results Show Different Profiles in Disease Monitoring for Ulcerative Colitis. |
| Q26765352 | Fecal immunochemical test as a biomarker for inflammatory bowel diseases: can it rival fecal calprotectin? |
| Q37523499 | Leucine-rich Alpha-2 Glycoprotein is a Serum Biomarker of Mucosal Healing in Ulcerative Colitis. |
| Q92417084 | Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam |
| Q53815697 | Mucosal Healing in Ulcerative Colitis: A Comprehensive Review. |
| Q57284265 | Patient self-reported symptoms using visual analog scales are useful to estimate endoscopic activity in ulcerative colitis |
| Q64075925 | Relationship between endoscopic mucosal healing and histologic inflammation during remission maintenance phase in ulcerative colitis: a retrospective study |
| Q37273489 | Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease |
| Q39251794 | Reviewing treatments and outcomes in the evolving landscape of ulcerative colitis |
| Q50262156 | Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis. |
| Q42409308 | Twice-daily Budesonide 2-mg Foam Induces Complete Mucosal Healing in Patients with Distal Ulcerative Colitis |
| Q24658603 | Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse |
Search more.